Financings Of The Fortnight Ponders A Post-Euro Financing Environment
This article was originally published in The Pink Sheet Daily
Plus news on recent financings by TopiVert, Dendreon, Inhibitex and Celsion.
You may also be interested in...
In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.
Biotech's primary liver cancer drug ThermoDox should produce pivotal Phase III data in the next 12 to 14 months.
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.